<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Guennoun R</submitter><funding>Burroughs Wellcome Fund</funding><funding>NCI NIH HHS</funding><pagination>2173</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9104311</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(9)</volume><pubmed_abstract>Lung cancer is the leading cause of cancer deaths in the United States and across the world. Immunotherapies, which activate tumor-infiltrating cytotoxic T lymphocytes, have demonstrated efficacy for the treatment of advanced-stage lung cancer. However, the potential for harnessing the immune system against the early stages of lung carcinogenesis to prevent cancer development and recurrence remains unexplored. Using a mouse model of lung adenocarcinoma, we investigated the effects of thymic stromal lymphopoietin (TSLP) induction on early cancer development in the lungs. Herein, we demonstrate that systemic TSLP induction suppressed spontaneous lung cancer development in Kras&lt;sup>G12D&lt;/sup> mice. TSLP drove a significant CD4&lt;sup>+&lt;/sup> T cell response to block lung cancer progression from </pubmed_abstract><journal>Cancers</journal><pubmed_title>Thymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development.</pubmed_title><pmcid>PMC9104311</pmcid><funding_grant_id>U01 CA233097</funding_grant_id><funding_grant_id>U01CA233097</funding_grant_id><funding_grant_id>CAMS</funding_grant_id><pubmed_authors>Hojanazarova J</pubmed_authors><pubmed_authors>Guennoun R</pubmed_authors><pubmed_authors>Schiferle EB</pubmed_authors><pubmed_authors>Stover MP</pubmed_authors><pubmed_authors>Trerice KE</pubmed_authors><pubmed_authors>Azin M</pubmed_authors><pubmed_authors>Demehri S</pubmed_authors><pubmed_authors>McGoldrick MT</pubmed_authors></additional><is_claimable>false</is_claimable><name>Thymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development.</name><description>Lung cancer is the leading cause of cancer deaths in the United States and across the world. Immunotherapies, which activate tumor-infiltrating cytotoxic T lymphocytes, have demonstrated efficacy for the treatment of advanced-stage lung cancer. However, the potential for harnessing the immune system against the early stages of lung carcinogenesis to prevent cancer development and recurrence remains unexplored. Using a mouse model of lung adenocarcinoma, we investigated the effects of thymic stromal lymphopoietin (TSLP) induction on early cancer development in the lungs. Herein, we demonstrate that systemic TSLP induction suppressed spontaneous lung cancer development in Kras&lt;sup>G12D&lt;/sup> mice. TSLP drove a significant CD4&lt;sup>+&lt;/sup> T cell response to block lung cancer progression from </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-18T21:52:40.691Z</modification><creation>2025-04-07T09:44:17.448Z</creation></dates><accession>S-EPMC9104311</accession><cross_references><pubmed>35565302</pubmed><doi>10.3390/cancers14092173</doi></cross_references></HashMap>